Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteer ≥ 2 years old;~* Proven legal identity;~* Written consent of the guardian of participants \< 18 years old, and written consent of the participant ≥ 12 years old;~* Complying with the requirement of the study protocol;~Exclusion Criteria:~* Prior vaccination with pneumococcal vaccine;~* History of bacterial pneumonia within 3 years prior to this study;~* Pregnant, breast feeding, or women expected to conceive within 60 days after vaccination;~* History of allergy to any vaccine or vaccine ingredient;~* Receipt of any of the following products:~  1. Blood product within 3 months prior to study entry;~ 2. Any live attenuated vaccine within 28 days prior to study entry;~ 3. Any subunit vaccine or inactivated vaccine within 14 days prior to study entry;~ 4. Any immunosuppressant within 6 month prior to study entry;~* Congenital malformation, developmental disorders, serious chronic diseases, autoimmune disease, immunodeficiency, serious cardiovascular disease, diabetes, hypertension that cannot be stabilized by medication, liver or kidney disease, or malignant tumor;~* History of asthma, thyroidectomy, angioneurotic edema, severe nervous system disease or mental illness; without spleen or splenectomy; diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities), or obvious bruising or coagulation disorders;~* Acute disease or acute stage of chronic disease within 7 days prior to study entry;~* Axillaty temperature \> 37.0 °C;~* Any other factor that in the opinion of the investigator suggesting the volunteer is unsuitable for this study;~* Participants with the following conditions from day 0 - 28 would be included in the full analysis set (FAS), but would be excluded from the per protocol set (PPS):~  1. Receipt of any other investigational or unregistered product (drug or vaccine);~ 2. Receipt of immunosuppressant (corticosteroid dosage that equivalent to or above 0.5 mg prednisone/kg weight/day) for \> 14 days, except for inhalant or locally administrated corticosteroid;~ 3. Receipt of immunoglobulin and/or blood product;~ 4. Newly diagnosed autoimmune disease or immunodeficiency (e.g., HIV infection);

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Experimental Group (Type: EXPERIMENTAL): * Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~* Intervention: investigational 23-valent PPV
- Control Group (Type: ACTIVE_COMPARATOR): * Single intramuscular injection of the control vaccine (0.5 ml) on Day 0~* Intervention: control 23-valent PPV

Based on this trial design, predict the completion outcome and termination type (if applicable).